ArticleAlimentary pharmacology & therapeutics2021

Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.

Maria Giulia Demarzo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.